Bayer profit flat as weak animal health offsets strong Xarelto

Bayer's adjusted core earnings were flat for the quarter, as better prescription numbers for cardiovascular drug Xarelto were tempered by a weaker animal health business and a strong euro weighing on the value of overseas sales. Sonia Legg reports.